Arcturus Therapeutics (ARCT) Tops Q1 EPS by 338c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.94, $3.38 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $5.24 million versus the consensus estimate of $6.3 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Keurig Dr Pepper coffee chief to depart ahead of planned split